Clinical TrialJun 11, 2026, 06:07 AM
Evaxion Presents Preclinical Data for AML Vaccine EVX-04
AI Summary
Evaxion A/S announced new preclinical data for its off-the-shelf therapeutic vaccine candidate, EVX-04, for acute myeloid leukemia (AML). The data shows successful expression and secretion of EVX-04 in human cells, leading to immune recognition and activation. The vaccine antigens demonstrated the ability to drive specific immune responses and induce targeted cell-killing in preclinical models. Evaxion plans to present these findings at the European Hematology Association (EHA) 2026 Congress.
Key Highlights
- Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia (AML).
- EVX-04 demonstrates complete expression and secretion in human cells, enabling immune recognition and activation.
- Vaccine antigens drive specific immune responses across different human immune profiles and induce targeted cell-killing.
- Data will be presented at a poster presentation at the European Hematology Association (EHA) 2026 Congress on June 13, 2026.
- EVX-04 targets multiple non-conventional endogenous retrovirus (ERV) tumor antigens from the dark genome.
Price Impact
More from EVAX